Cadrenal Therapeutics, Inc - CVKD Earnings per share for the last 12 months

This GURU.Markets daily chart illustrates the annual shift in EPS TTM, where the 44.50 level reflects the parameter's status. Cadrenal Therapeutics (CVKD) is developing Inertia, a unique anticoagulant for renal failure, which is expected to generate monopoly demand. The business model relies on outsourcing production and testing; however, the lack of sales makes the company's valuation dependent on clinical trial results.
cadrenal.com - analytical breakdowns and key metrics (CVKD)

This metric measures the relative change in earnings per share over a rolling twelve-month period, reflecting the rate of profit capitalization relative to the volume of issuance. By analyzing this rolling annual EPS growth chart, an investor can assess the scaling efficiency of tecafarin and the impact of Phase III trial costs on the final shareholder returns for Cadrenal Therapeutics (CVKD).